However, the HFrEF group had more patients with dilated cardiomyopathy (DCM) and patients receiving β-blocker drugs or mineralocorticoid receptor antagonist (MRA) drugs. The gene discussed is NR3C2; the disease is familial dilated cardiomyopathy.